Your browser doesn't support javascript.
loading
Survival outcomes in locally advanced cutaneous squamous cell carcinoma presenting with clinical perineural invasion alone.
Hazim, Antonious Z; Reed, Clay T; Price, Katharine A; Foote, Robert L; Ma, Daniel J; Neben-Wittich, Michelle; DeLone, David R; Jenkins, Sarah M; Smith, Carin Y; Chintakuntlawar, Ashish V.
Afiliación
  • Hazim AZ; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Reed CT; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Price KA; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Foote RL; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Ma DJ; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Neben-Wittich M; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • DeLone DR; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Jenkins SM; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
  • Smith CY; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
  • Chintakuntlawar AV; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Head Neck ; 43(7): 1995-2001, 2021 07.
Article en En | MEDLINE | ID: mdl-33644935
ABSTRACT

BACKGROUND:

Cutaneous squamous cell carcinomas (CSCC) involving the head and neck are common, but initial presentation or recurrence limited to the cranial nerves is rare.

METHODS:

We conducted a retrospective study of 21 patients with clinical perineural invasion (PNI) from CSCC and no measurable disease by RECIST 1.1. Patients treated with radiotherapy or chemoradiotherapy were included.

RESULTS:

The median time from symptom onset until diagnosis was 13.0 months (2.6-83.1). All patients received radiotherapy. Fourteen received concurrent systemic therapy. The median follow-up time was 30.5 months (1.1-106.0). Ten patients recurred, with the majority being locoregional. The 2-year overall survival rate was 85%. The median progression-free survival (PFS) was 21.5 months with an estimated 2-year PFS of 44.5% (95%CI 22.3-66.8).

CONCLUSIONS:

CSCCs with clinical PNI alone are difficult to diagnose and can have a long interval between appearance of symptoms and diagnosis. They can successfully be treated with chemoradiotherapy. However, many patients still suffer from locoregional recurrences.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Carcinoma de Células Escamosas / Neoplasias de Cabeza y Cuello Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Head Neck Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Carcinoma de Células Escamosas / Neoplasias de Cabeza y Cuello Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Head Neck Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos